Protein Distribution and Leucine Supplementation Effects on Body Composition and Performance in Tactical Athletes

Официальное название

The Effect of Protein Distribution and Leucine Supplementation on Body Composition, Physical Performance, and Myofibrillar Damage in Tactical Athletes: a Randomized Controlled Trial During 8 Weeks of Intensive Training

Обзор

This randomized controlled trial will examine the effects of within-day protein distribution and leucine supplementation on body composition, physical performance, and biomarkers of muscle damage in tactical athletes during an 8-week intensive training program. Sixty-nine healthy male participants (18-35 years) enrolled in a Ministry of Defense training course will be randomly assigned to one of three iso-caloric dietary groups providing 1.6 g/kg/day of protein: (1) evenly distributed protein across three meals (EVEN), (2) a 16-hour daily protein fasting pattern with protein concentrated at lunch and dinner (FAST), or (3) the same fasting pattern with 5 g leucine supplementation at breakfast (FAST-RESCUE). Primary outcomes include changes in lean body mass. Secondary outcomes include strength, anaerobic performance, and biochemical markers of muscle damage, including urinary titin N-terminal fragment (UTF). Assessments will be conducted at baseline, Week 5, and Week 8.

Подробное описание

This study is an 8-week, three-arm, parallel-group randomized controlled trial conducted in healthy male tactical trainees (18-35 years) enrolled in a Ministry of Defense training program. Participants will undergo a high-volume concurrent training regimen exceeding 30 hours per week, including resistance training, load carriage, aerobic conditioning, and combat-based drills.

Participants (n=69) will be randomized in a 1:1:1 ratio to one of three iso-caloric dietary interventions providing 1.6 g/kg/day of protein:

1. EVEN: Protein evenly distributed across three daily meals (08:00, 13:00, 18:00). 2. FAST: Skewed protein distribution with a 16-hour protein-free window (21:00-13:00), omitting protein at breakfast and concentrating intake at lunch and dinner. 3. FAST-RESCUE: Identical to FAST, with addition of 5 g free-form leucine consumed at breakfast.

Energy intake will be individualized based on measured resting metabolic rate and estimated physical activity level. Dietary adherence will be monitored daily using a mobile application and weekly dietitian supervision.

Primary Outcome:

\- Change in lean body mass measured by bioelectrical impedance analysis from baseline to Week 8.

Secondary Outcomes:

* Maximal strength (isometric mid-thigh pull, maximal voluntary contraction, handgrip strength) * Anaerobic performance (Wingate test, countermovement jump) * Serum biomarkers (creatine kinase, urea, testosterone, inflammatory markers) * Urinary titin N-terminal fragment to creatinine ratio (UTF/Cr) as a marker of myofibrillar damage

Assessments will be performed at baseline, Week 5, and Week 8. Data will be analyzed according to the intention-to-treat principle using linear mixed models to evaluate Group × Time interactions.

Вмешательства

• Пищевая добавка L-leucine supplementation
  Participants ingest 5 g free-form L-leucine at breakfast (\~08:00) daily for 8 weeks. Leucine is provided as unflavored, pharmaceutical-grade instantized powder, reconstituted in water and consumed at the protein-free breakfast meal.
• Поведенческое Even Protein Distribution
  Iso-caloric diet providing 1.6 g/kg/day protein evenly distributed across three daily meals for 8 weeks.
• Поведенческое Skewed Protein Distribution (16-hour Protein-Fasting Window)
  Iso-caloric diet providing 1.6 g/kg/day protein with protein omitted at breakfast and concentrated at lunch and dinner, creating a 16-hour daily protein-free window for 8 weeks.

Первичные конечные точки

• Change in Lean Body Mass (LBM) [Срок оценки: Baseline (Week 1) to Week 8]

Вторичные конечные точки (12)

• Change in Fat Mass Percentage [Срок оценки: Baseline (Week 1), Week 5, and Week 8]
• Change in Fat-Free Mass (FFM) [Срок оценки: Baseline (Week 1), Week 5, and Week 8]
• Change in Skeletal Muscle Mass (SMM) [Срок оценки: Baseline (Week 1), Week 5, and Week 8]
• Change in Maximal Strength - Isometric Mid-Thigh Pull (IMTP) [Срок оценки: Baseline (Week 1), Week 5, and Week 8]
• Change in Maximal Voluntary Isometric Contraction (MVC) [Срок оценки: Baseline (Week 1), Week 5, and Week 8]
• Change in Handgrip Strength [Срок оценки: Baseline (Week 1), Week 5, and Week 8]
• Change in Countermovement Jump (CMJ) Performance [Срок оценки: Baseline (Week 1), Week 5, and Week 8]
• Change in Peak Power Output (Wingate Test) [Срок оценки: Baseline (Week 1), Week 5, and Week 8]
• Change in Mean Power Output (Wingate Test) [Срок оценки: Baseline (Week 1), Week 5, and Week 8]
• Change in Urinary Titin N-terminal Fragment to Creatinine Ratio (UTF/Cr) [Срок оценки: Baseline (Week 1) and Week 5]
• Change in Serum Creatine Kinase (CK) [Срок оценки: Baseline (Week 1), Week 5, and Week 8]
• Change in Serum Urea (Blood Urea Nitrogen, BUN) [Срок оценки: Baseline (Week 1), Week 5, and Week 8]

Критерии участия

Критерии включения

• Male participants aged 18-35 years
• Enrolled in an active Ministry of Defense tactical training program
• Physically active and medically cleared to participate in intensive training
• Willing and able to comply with the dietary intervention and training protocol
• Provide written informed consent prior to participation

Критерии исключения

• Musculoskeletal or neuromuscular injury or impairment limiting participation in exercise training
• Cardiopulmonary disease (including recent myocardial infarction or unstable angina)
• History of cancer, diabetes, thyroid disease, hypertension, or chronic renal failure
• Cognitive impairment affecting ability to provide informed consent
• Use of medications that may affect metabolism, muscle physiology, or exercise performance
• Known allergy or intolerance to study dietary components or leucine supplementation
• Non-compliance with study protocol requirements

Критерии приведены из реестра в оригинале (на английском). Окончательную оценку соответствия проводит исследовательский центр.

Здоровые добровольцы: Да

Дизайн исследования

Распределение

Рандомизированное

Модель

Параллельные группы

Маскирование

Открытое

Основная цель

Профилактика

Центры проведения

Список центров уточняется — проверьте первичный протокол.

Идентификаторы

NCT: NCT07438158 · 0011980-1

Первоисточники (государственные реестры)

• ClinicalTrials.gov (NIH, США)

Открыть это исследование на ClinicalTrials.gov ↗